Abivax (ABVX) Q2 2026 earnings review
Mega-raise secures runway, but Crohn's pipeline stalls
Abivax reported zero revenue and a Q2 net loss of €117.4 million, heavily impacted by a €43.2 million non-cash loss from repurchasing its royalty certificates. Operating cash burn accelerated to €102.5 million in the first half as R&D expenses jumped 51% year-over-year. Following the quarter, the company raised an $874 million gross on Nasdaq, pushing pro-forma cash above €1.15 billion.
⚖️ Verdict: 🟢 Bullish
The case is better — a bullish verdict — because the financing and royalty buyout fundamentally secure the company's future and unit economics. The capital raise funds the company well past its Q4 2026 ulcerative colitis NDA submission, while settling the 2% top-line encumbrance on obefazimod for $90 million clears the path for highly profitable commercialization if approved.
What the print did not settle is the cost of the broader pipeline delay. With the Crohn's Phase 2b data pushed from late 2026 to mid-2027, the company is entirely dependent on the UC indication's approval to justify the massive acceleration in sales and marketing expenses.
🐂 Bull Case
The July Offering Clears the Financing Overhang
The defining event for Abivax occurred just after the quarter closed. In July 2026, the company raised $874.1 million in a Nasdaq offering, yielding €767.1 million net. Combined with the €388.0 million in cash on the balance sheet at the end of June, pro-forma liquidity now exceeds €1.15 billion.
This capitalization removes the immediate going-concern risk that defined previous filings. The cash on hand fully funds the company through the critical Q4 2026 New Drug Application submission for obefazimod in ulcerative colitis, and secures the runway well into the initial U.S. commercial launch phase.
Buying Back the Royalty Secures Unit Economics
In May, Abivax settled its outstanding royalty certificates for $90 million, paid half in cash and half in equity. This extinguishes a 2% perpetual top-line encumbrance on all future obefazimod sales.
While the transaction forced a €43.2 million non-cash loss on derecognition in Q2 — skewing the headline net loss heavily downward — it is highly accretive to the long-term thesis. For a late-stage asset addressing the multi-billion-dollar ulcerative colitis market, trading a fixed $90 million upfront for a permanent 2% gross margin expansion is a clear structural upgrade.
🐻 Bear Case
Crohn's Data and Pipeline Pushed Out
Management highlights the ongoing success of the ulcerative colitis program, but the broader platform is stalling. The Phase 2b ENHANCE-CD trial in Crohn's disease — originally guided for a readout in the second half of 2026 — is now expected in mid-2027. Similarly, the selection of a follow-on compound has been pushed into late 2026, and preclinical combination data was delayed.
These deferrals isolate the company entirely to a single binary event. Without the Crohn's data or follow-on compounds reading out this year, the entire $1.15 billion war chest and accelerating commercial build rest solely on the ulcerative colitis indication.
Share-Based Comp Distorts Earnings and Dilutes the Base
Operating expenses nearly doubled year-over-year to €85.3 million in Q2, but much of that headline figure stems from an aggressive internal equity plan. Share-based compensation and related employer taxes contributed €23.7 million to the R&D expense increase in the first half, and another €6.1 million to the G&A increase.
While labeled a non-cash expense, the dilution is real. The weighted average share count rose 25.5% year-over-year even before accounting for the 7.36 million new ADSs issued in the July capital raise.
Commercial Prep Drives Steep Cash Burn
Even stripping out the accounting noise of the royalty buyout and share-based compensation, core cash usage is accelerating rapidly. Net cash used in operating activities reached €102.5 million in the first half, a 53.8% increase over the prior year.
The primary driver is the early build-out of the U.S. commercial organization. Sales and marketing expenses jumped 328% year-over-year in Q2. Establishing a commercial footprint for a drug not yet submitted for approval guarantees elevated cash burn for at least the next 18 months.
💲 Other KPIs
Down from €516.7 million at the end of 2025, reflecting H1 operating burn and the $45 million cash portion of the royalty repurchase. This balance is prior to the July capital raise.
Slightly down from €1.05 million a year ago. The statutory cap on outsourced R&D limits the upside here despite R&D expenses climbing 51% year-over-year.
🔮 Guidance
Confirmed the planned submission timeline to the FDA for adults with moderately to severely active ulcerative colitis, following a positive pre-NDA interaction.
Delayed the 12-week induction readout for Crohn's disease from the previously guided second half of 2026 to mid-2027.
Pushed the announcement of a follow-on compound selection into late 2026.